ESTEVE's research and innovation activity has been rated ''Excellent'' by the Profarma Plan (the Plan for the Promotion of Scientific Research, Development and Technological Innovation in the Pharmaceutical Industry), of the Ministry of Economy, Industry and Competitiveness and of the Ministry of Health, Social Services and Equality. This program has existed without interruption for the last 32 years and the company has achieved the highest possible score.

The rating of ''Excellent'' allows ESTEVE to be included in Group A of the Profarma Plan, a category that recognizes companies with significant research activity and their own basic or clinical R&D centers. Since 2012, all key units for drug discovery and preclinical development have been located in a 2,400 m2 facility in the Science Park of the University of Barcelona (PCB).

The fundamental objective of the Profarma Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector and promoting activities that provide greater added value, such as investment in new industrial plants and new production technologies, and by encouraging research, development and innovation. The Profarma Plan rates companies as ''Excellent'', ''Very Good'', ''Good'' or ''Acceptable''.